Breast Cancer Stem Cell Potency of Nickel(II)-Polypyridyl Complexes Containing Non-steroidal Anti-inflammatory Drugs

Catherine J. Feld+, Alice Johnson+, Zhiyin Xiao, and Kogularamanan Suntharalingam*[a]
Table of Content

Figure S1. ATR-FTIR spectra of (A) 1, (B) 2, (C) 3, and (D) 4 in the solid form.

Figure S2. UV-Vis spectra of 1-4 (50 μM) in chloroform at room temperature.

Table S1. Experimentally determined LogP values for 1-4.

Figure S3. UV-Vis spectrum of 1 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

Figure S4. UV-Vis spectrum of 2 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

Figure S5. UV-Vis spectrum of 3 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

Figure S6. UV-Vis spectrum of 4 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

Figure S7. UV-Vis spectrum of 1 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

Figure S8. UV-Vis spectrum of 3 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

Figure S9. UV-Vis spectrum of 2 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

Figure S10. UV-Vis spectrum of 4 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

Figure S11. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with 1.

Figure S12. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with 3.

Figure S13. Chemical structures of the copper(II)-3,4,7,8-tetramethyl-1,10-phenanthroline complexes containing the non-steroidal anti-inflammatory drugs (NSAIDs), naproxen and indomethacin. Cu-1 and Cu-3.

Figure S14. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with NiCl₂·6H₂O.

Figure S15. Representative dose-response curves for the treatment of MCF10A cells with 1 and 3.

Figure S16. Quantification of mammosphere formation with HMLER-shEcad cells untreated and treated with NiCl₂·6H₂O (at 2 μM for 5 days). Error bars = SD.

Figure S17. Representative bright-field images (x 10) of the mammospheres in the absence and presence of NiCl₂·6H₂O (at 2 μM for 5 days).

Figure S18. Representative dose-response curves for the treatment of HMLER-shEcad mammospheres with 1, 3, NiCl₂·6H₂O, or naproxen after 5 days incubation.

Figure S19. Representative histograms displaying the green fluorescence emitted by anti-COX-2 Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 μM) for 24 h (red) followed by 72 h in media containing naproxen (20 μM, blue) or indomethacin (20 μM, orange).

Figure S20. Representative histograms displaying the green fluorescence emitted by anti-COX-2 Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 μM) for 24 h (red) followed by 72 h in media containing NiCl₂·6H₂O (20 μM, blue).
**Figure S21.** Representative dose-response curves for the treatment of HMLE-shEcad cells with 1 after 72 incubation in the presence and absence of PGE2 (20 μM).

**Figure S22.** Representative dose-response curves for the treatment of HMLE-shEcad cells with 1 after 72 incubation in the presence and absence of IM-54 (10 μM), necrostatin-1 (20 μM), or dabrafenib (20 μM).

**Figure S23.** Representative dose-response curves for the treatment of HMLE-shEcad cells with 3 after 72 incubation in the presence and absence of IM-54 (10 μM), necrostatin-1 (20 μM), or dabrafenib (20 μM).

**Figure S24.** Graphical representation of the IC$_{50}$ values of 1 against HMLE-shEcad cells in the absence and presence of IM-54 (10 μM), necrostatin-1 (20 μM), or dabrafenib (10 μM). Error bars represent standard deviations and Student t-test, * = p < 0.05.
Figure S1. ATR-FTIR spectra of (A) 1, (B) 2, (C) 3, and (D) 4 in the solid form.

Figure S2. UV-Vis spectra of 1-4 (50 μM) in chloroform at room temperature.
Table S1. Experimentally determined LogP values for 1-4.

| Metal complex | LogP      |
|---------------|-----------|
| 1             | 0.63 ± 0.05 |
| 2             | 1.21 ± 0.11 |
| 3             | 0.96 ± 0.13 |
| 4             | 1.52 ± 0.14 |

Figure S3. UV-Vis spectrum of 1 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.
**Figure S4.** UV-Vis spectrum of 3 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

**Figure S5.** UV-Vis spectrum of 2 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.
Figure S6. UV-Vis spectrum of 4 (50 μM) in PBS:DMSO (200:1) over the course of 24 h at 37 °C.

Figure S7. UV-Vis spectrum of 1 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.
Figure S8. UV-Vis spectrum of 3 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

Figure S9. UV-Vis spectrum of 2 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.
**Figure S10.** UV-Vis spectrum of 4 in mammary epithelial cell growth medium (MEGM):DMSO (200:1) over the course of 24 h at 37 °C.

**Figure S11.** Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with 1.
Figure S12. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with 3.

Figure S13. Chemical structures of the copper(II)-3,4,7,8-tetramethyl-1,10-phenanthroline complexes containing the non-steroidal anti-inflammatory drugs (NSAIDs), naproxen and indomethacin, Cu-1 and Cu-3.
Figure S14. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad cells with NiCl$_2$·6H$_2$O.

Figure S15. Representative dose-response curves for the treatment of MCF10A cells with 1 and 3.
Figure S16. Quantification of mammosphere formation with HMLER-shEcad cells untreated and treated with NiCl$_2$·6H$_2$O (at 2 µM for 5 days). Error bars = SD.

Figure S17. Representative bright-field images (x 10) of the mammospheres in the absence and presence of NiCl$_2$·6H$_2$O (at 2 µM for 5 days).
**Figure S18.** Representative dose-response curves for the treatment of HMLER-shEcad mammospheres with 1, 3, NiCl$_2$·6H$_2$O, or naproxen after 5 days incubation.

**Figure S19.** Representative histograms displaying the green fluorescence emitted by anti-COX-2 Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 µM) for 24 h (red) followed by 72 h in media containing naproxen (20 µM, blue) or indomethacin (20 µM, orange).
Figure S20. Representative histograms displaying the green fluorescence emitted by anti-COX-2 Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 μM) for 24 h (red) followed by 72 h in media containing NiCl$_2$·6H$_2$O (20 µM, blue).

Figure S21. Representative dose-response curves for the treatment of HMLER-shEcad cells with 1 after 72 incubation in the presence and absence of PGE2 (20 µM).
**Figure S22.** Representative dose-response curves for the treatment of HMLER-shEcad cells with 1 after 72 incubation in the presence and absence of IM-54 (10 μM), necrostatin-1 (20 μM), or dabrafenib (20 μM).

**Figure S23.** Representative dose-response curves for the treatment of HMLER-shEcad cells with 3 after 72 incubation in the presence and absence of IM-54 (10 μM), necrostatin-1 (20 μM), or dabrafenib (20 μM).
Figure S24. Graphical representation of the IC$_{50}$ values of 1 against HMLER-shEcad cells in the absence and presence of IM-54 (10 µM), necrostatin-1 (20 µM), or dabrafenib (10 µM). Error bars represent standard deviations and Student t-test, * = $p < 0.05$. 

![IC$_{50}$ values graph](image)